|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Three monfhly intravenous injection of ibandonat in the treatment of postmenopausal osteoporosis显示文摘 | Thiebaud D Burckhardt P Kriegbaum H | 1997 | American J MED1997，103，： | 1 |
| 2 | Spinal lesions in patients with ankylosing spondylitis显示文摘 | Pedersen W Clausen S Kriegbaum NJ | 1987 | Scand J Rheumatol1987，16，5： | 1 |
| 3 | Rational targeting of the urokinase receptor (uPAR) : development of antagonists and non-invasive imaging probes显示文摘 | Kriegbaum MC Persson M Haldager L | 2011 | Curr Drug Targets2011，12，12： | 1 |
| 4 | Three monthly intravenous injections of ibandronate in the treatment of postmenopausal asteoporosis显示文摘 | Thiebaud D Burckhardt P Kriegbaum H | 1997 | Am G Med1997，103，4： | 1 |
| 5 | Spinallesions in patients with ankylosing spondylitis显示文摘 | Pedersen W Clausen S Kriegbaum NJ | 1987 | Scand J Rheumatol1987，16，5： | 1 |
| 6 | Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis显示文摘 | Burckhardt P Kriegbaum H | 1997 | Am J Med1997，103，4： | 1 |
| 7 | Spinal lesions in patients with ankylosing spondyiitis显示文摘 | Pedersen W Clausen S Kriegbaum N J | 1987 | Scand J Rheumatol1987，16，5： | 1 |
| 8 | Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25 hydroxyvitamin D3 in patients with systemic lupus erythematosus显示文摘 | MOiler K Kriegbaum NJ Baslund B | 1995 | Clin Rheumatol1995，14，4： | 1 |
| 9 | Three monthly intravenous of ibandronate in the treatment of postmenopausal osteoporosis显示文摘 | Thiebaud D Burckhardt P Kriegbaum H | 1997 | Am J Med1997，103，4： | 1 |
| 10 | Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis 显示文摘 | Thiebaud D Burckhardt Kriegbaum H | 1997 | Am G Med1997，103，4： | 1 |
| 11 | Prevention of deformation(disability)in rheumatoid arthritis显示文摘 | | 2000 | Ugeskr Laeger2000，162，11： | 1 |
| 12 | Three monthly intravenous injections of ibandronate in the treatment of postmenopausal显示文摘 | Thiebaud D Burckhardt P Kriegbaum H | 1997 | Am J Med1997，103，4： | 1 |
| 13 | An 8-year follow-up study of pulmonary function in patients with rheumatoid arthritis显示文摘 | Linstow M Ulrik CS Kriegbaum NJ | | 0，，： | 1 |
| 14 | Three monthly intravenous injections of ibandronate in the treatment of post menopausal显示文摘 | Thiebaud D Burckhardt P Kriegbaum H | 1997 | Am J Med1997，103，4： | 1 |
| 15 | The influence of birth weight and body mass in early adulthood on early coronary heart disease risk among Danish men born in 1953显示文摘 | Osler M Lund R Kriegbaum M | 2009 | Eur J Epidemiol2009，24，1： | 1 |
| 16 | Rational targeting of the urokinase receptor(uPAR):development of antagonists and non-invasive imaging probes显示文摘 | Kriegbaum MC Persson M Haldager L | 2011 | Curr Drug Targets2011，12，12： | 1 |
| 17 | Three monthly intravenous injection of ibandronate in the tre- atment of postmenopausal osteoporosis显示文摘 | Thiebaud D Burck hardt Kriegbaum H | 1997 | Am J Med1997，103，： | 1 |
| 18 | Expression-level dependent activation of recombinant human parathyroid hormone/ parathyroid hormone-related peptide receptor:effect of human parathyroid hormone(1-34) (1-31) and (28-48)显示文摘 | Tonn O Kriegbaum S Braitmaier A | 2000 | Recept signal Transduct Res2000，20，23： | 1 |
| 19 | C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma显示文摘The high prevalence and mortality of lung cancer, together with a poor 5-year survival of only approximately 15%, emphasize the need for prognostic and predictive factors to improve patient treatment. C4.4A, a member of the Ly6/uP AR family of membrane proteins, qualifies as such a potential informative biomarker in non-small cell lung cancer. Under normal physiological conditions, it is primarily expressed in suprabasal layers of stratified squamous epithelia. Consequently, it is absent from healthy bronchial and alveolar tissue, but nevertheless appears at early stages in the progression to invasivecarcinomas of the lung, i.e., in bronchial hyperplasia/metaplasia and atypical adenomatous hyperplasia. In the stages leading to pulmonary squamous cell carcinoma, expression is sustained in dysplasia, carcinoma in situ and invasive carcinomas, and this pertains to the normal presence of C4.4A in squamous epithelium. In pulmonary adenocarcinomas, a fraction of cases is positive for C4.4A, which is surprising, given the origin of these carcinomas from mucin-producing and not squamous epithelium. Interestingly, this correlates with a highly compromised patient survival and a predominant solid tumor growth pattern. Circumstantial evidence suggests an inverse relationship between C4.4A and the tumor suppressor LKB1. This might provide a link to the prognostic impact of C4.4A in patients with adenocarcinomas of the lung and could potentially be exploited for predicting the efficacy of treatment targeting components of the LKB1 pathway. | Benedikte Jacobsen Mette Camilla Kriegbaum Eric Santoni-Rugiu Michael Ploug | 2014 | World Journal of Clinical Oncology2014，5，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员